April 25, 2017 1:35 PM ET

Biotechnology

Company Overview of Enanta Pharmaceuticals, Inc.

Key Executives for Enanta Pharmaceuticals, Inc.

NameBoard RelationshipsTitleAge
Jay R. Luly Ph.D.35 RelationshipsChief Executive Officer, President and Director60
Paul J. Mellett Jr.No RelationshipsChief Financial Officer and Senior Vice President of Finance & Administration61
Nathalie Adda M.D.No RelationshipsChief Medical Officer and Senior Vice President50
Nathaniel S. Gardiner J.D.No RelationshipsSenior Vice President, General Counsel and Secretary62
Timothy D. Ocain Ph.D.10 RelationshipsSenior Vice President of New Product Strategy and Development58
View More Key Executives

Enanta Pharmaceuticals, Inc. Board Members*

NameBoard RelationshipsPrimary CompanyAge
Bruce L. A. Carter Ph.D. 200 RelationshipsEnanta Pharmaceuticals, Inc.73
Jay R. Luly Ph.D. 35 RelationshipsEnanta Pharmaceuticals, Inc.60
Terry C. Vance 26 RelationshipsBioMotiv, LLC58
Stephen Buckley Jr. 15 RelationshipsEnanta Pharmaceuticals, Inc.66
George S. Golumbeski Ph.D. 23 RelationshipsEnanta Pharmaceuticals, Inc.59
View All Board Members

Enanta Pharmaceuticals, Inc. Executive Committees*

Committee NameChairpersonBoard RelationshipsMembers
Audit Committee Jr.Stephen Buckley15 Relationships2 Executives
Compensation Committee Ph.D.George S. Golumbeski23 Relationships3 Executives
Nominating Committee Terry C. Vance26 Relationships4 Executives
Corporate Governance Committee Terry C. Vance26 Relationships4 Executives
View Committee Details
*Data is at least as current as the most recent Definitive Proxy.
 

The information and data displayed in this profile are created and managed by S&P Global Market Intelligence, a division of S&P Global. Bloomberg.com does not create or control the content. For inquiries, please contact S&P Global Market Intelligence directly by clicking here.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

CEO COMPENSATION IN THIS INDUSTRY

  Industry Range
Salary$542.4K
542.4K
375.6K
Bonus
Not meaningful
Total Short Term Compensation$1.6M
1.6M
470.4K
Total Value of Options$542.4K
542.4K
14.1M
Compensation as of Fiscal Year 2016
Enanta Pharmaceuticals, Inc. CEO Compensation
Industry Average

INDUSTRY EXECUTIVE CHANGES

Circassia Pharmaceuticals plc Announces the Retirement of Charles Swingland and Tim Corn as Non-Executive Directors
April 25, 2017 6:02 AM ET
biOasis Technologies Inc. Announces Executive Changes
April 24, 2017 9:07 PM ET
Tetra Bio-Pharma Inc. Appoints Denis Courchesne as Vice President, Sales, Effective May 1, 2017
April 24, 2017 8:17 PM ET
Heron Therapeutics, Inc. Appoints Robert E. Hoffman as Chief Financial Officer and Senior Vice President, Finance
April 24, 2017 8:05 PM ET
Immune Pharmaceuticals Inc. Announces Executive Changes
April 24, 2017 12:30 PM ET

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact Enanta Pharmaceuticals, Inc., please visit . Company data is provided by S&P Global Market Intelligence. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.